A study of the alternating administration of ixabepilone and vinflunine every three weeks in patients with advanced cancer
Latest Information Update: 19 May 2008
At a glance
- Drugs Ixabepilone (Primary) ; Vinflunine (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 16 May 2008 Status changed from in progress to completed.
- 25 Apr 2008 Planned patient number and estimated study completion date updated from ClinicalTrials.gov
- 07 Mar 2008 Status changed from recruiting to in progress, according to ClinicalTrials.gov